Clinical Trials Directory

Trials / Completed

CompletedNCT05203731

Level of Physical Activity and Fear Learning

The Role of Exercise in the Consolidation of Fear Extinction Learning in Adults With High Anxiety Sensitivity

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
54 (actual)
Sponsor
NYU Langone Health · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The proposed experimental study will be the first to investigate whether exercise vs. sitting enhances consolidation of extinction learning in adults with high AS and anxiety disorders, and the mechanistic pathways of expectancy, affect, and key stress response markers.

Detailed description

This is an experimental study (not a treatment study) aiming to examine the effects of acute exercise vs. sitting on fear extinction learning in a 2-day paradigm. 50 eligible (after screening) men and women ages 18-60 with high anxiety sensitivity (AS) and an anxiety disorder (generalized anxiety disorder, panic disorder, social anxiety disorder) will participate in a consecutive 2-day paradigm. Participants will be randomized to 1 of 2 conditions immediately following the emotional learning paradigm: 1) moderate intensity exercise (n=25) or 2) sitting(n=25), for 20 minutes. Day 2 will include testing of emotional learning. Primary outcomes are physiological arousal (skin conductance, heart rate) during Day 2 procedures. Mechanistic factors, including expected negative consequences of exercise, affect during exercise, threat/shock expectancy, and changes pre-post exercise in stress related neuroendocrine markers (cortisol and alpha-amylase) and their effects on extinction recall will be measured.

Conditions

Interventions

TypeNameDescription
BEHAVIORALExerciseModerate intensity exercise (typically a brisk walk or light run) will occur for 20 minutes after the emotional learning procedures on Day 1.
BEHAVIORALSittingSitting will occur for 20 minutes after the emotional learning procedures on Day 1.

Timeline

Start date
2023-01-31
Primary completion
2025-03-19
Completion
2025-03-19
First posted
2022-01-24
Last updated
2026-02-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05203731. Inclusion in this directory is not an endorsement.